BMS-5 (LIMKi 3) is a Potent LIM kinase inhibitor (IC50 values are 7 and 8 nM for LIMK1 and LIMK2 respectively). BMS-5 inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. BMS-5 reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay. COCs exhibited different diffusion situation between control and treatment group: the diffusion of 200 µM BMS-5 (LIMKi 3) treated-COCs was significantly weaker than the control group. In the standard of COCs surrounded by the cumulus cell layers, we counted the proportion of diffusion and found that the rate of good diffusion was decreased significantly (40.05 ± 3.03% vs. 20.50 ± 4.05%; p < 0.05). Oocytes were then obtained from COCs after hyaluronidase treatment, we found that few oocytes extruded the polar body after 200 µM BMS-5 (LIMKi 3) treatment.
Cell Experiment | |
---|---|
Cell lines | COCs |
Preparation method | For LIMK1/2 inhibitor treatment, stock LIMKi 3 (50 mM in dimethylsulfoxide (DMSO)) was diluted in M199 to final concentrations of 50, 100, 150 and 200 µM. A control group was cultured in DMSO at the same relative concentration of solvent. COCs were cultured with LIMKi 3 to evaluate its effects on oocyte maturation. COCs were denuded of their cumulus cells by gentle pipetting with 0.1% (w/v) hyaluronidase. |
Concentrations | 200 µM |
Incubation time | 44 h |
Animal Experiment | |
---|---|
Animal models | NF1+/− mice |
Formulation | DMEM × 1 containing 5% FCS |
Dosages | 0, 25 or 50 μM |
Administration | i.v. |
Molecular Weight | 431.29 |
Formula | C17H14Cl2F2N4OS |
CAS Number | 1338247-35-0 |
Solubility (25°C) | DMSO ≥ 30 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Jia RX, et al. PeerJ. LIMK1/2 inhibitor LIMKi 3 suppresses porcine oocyte maturation.
Related Products |
---|
Izeltabart
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C to synthesize IMGC936, an Antibody-drug Conjugate with strong anti-cancer activity. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models. |
Cofetuzumab
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. |
Crizanlizumab
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs). |
M3554 (anti-GD2 ADC)
M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody. M3554 has anti-tumor activity. |
OGT2115
OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.